CoChat

The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries

Open access
Wong, Angel Y.S., Hsia, Yingfen, Chan, Esther W., Murphy, Declan G.M., Simonoff, Emily, Buitelaar, Jan K., Wong, Ian C.K. · 2014 · Autism Research
Cited by 31

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

There is significant variation in prescriptions among countries in clinical practice for the treatment of comorbidities associated with autism spectrum disorder (ASD). It has been suggested that many people with mental health disorders in low‐/middle‐income countries do not receive adequate treatment. Hence, this study investigated psychopharmacological treatment patterns for ASD comorbidities in 30 countries and the association between country's income and prescription rates. The IMS Prescribing Insights database was used to investigate prescription patterns for ASD comorbidity treatment from 2007 to 2012. Data were obtained from 30 countries in continents of E urope, A sia, O ceania, C entral A merica, S outh A merica, and A frica. The gross domestic product (GDP) per capita was used as a proxy for each country's income. S pearman correlation was used to examine the association between prescription rate and GDP per capita. The highest prescription rates were found in W estern E urope (3.89–36.36/10,000) while the lowest prescription rates were found in A sian countries, such as T urkey, I ndonesia, S audi A rabia, and P akistan (0.04–0.82/10,000). The most commonly prescribed drug for ASD comorbidity treatment in most of the countries was risperidone, but antidepressants and antiepileptic drugs were also frequently prescribed. There was a significant positive correlation between GDP per capita and prescription rate (S pearman ρ = 0.60; P = 0.0011; 95% confidence interval 0.27–0.81), that is, the higher the GDP per capita, the higher the prescription rate. There are marked international differences in prescription rates, and this is partially accounted by economic factors. Future research should combine more data for ASD comorbidity treatment to explore the disparity of psychopharmacological treatment between countries. Autism Res 2014, 7: 543–554. © 2014 International Society for Autism Research, Wiley Periodicals, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/aur.1391

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 31

Metadata

Authors
Wong, A. Y. S., Hsia, Y., Chan, E. W., Murphy, D. G. M., Simonoff, E., Buitelaar, J. K., & Wong, I. C. K.
Venue
Autism Research
Publisher
Wiley
Published
2014-06-03
Volume
7
Issue
5
Pages
543-554
ISSN
  • 1939-3792 (ISSN-L)
  • 1939-3806
OpenAlex
W2135207343
Cited by
31
References
14
FWCI
2.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.